TABLE 6.
Fractional target attainment for different ceftriaxone dosing regimens and bacterial speciesa
| Dose | CLCR (mL/min) | Albumin (g/L) | Fractional target attainment in: |
||||
|---|---|---|---|---|---|---|---|
| E. coli | H. influenzae | K. pneumoniae | S. pneumoniae | S. aureus | |||
| 1 g q24h | 40 | 20 | 1 | 0.99 | 1 | 0.96 | 0.20 |
| 40 | 30 | 1 | 1 | 1 | 0.97 | 0.23 | |
| 40 | 40 | 1 | 1 | 1 | 0.98 | 0.24 | |
| 100 | 20 | 1 | 0.98 | 0.98 | 0.92 | 0.06 | |
| 100 | 30 | 1 | 0.99 | 0.99 | 0.95 | 0.08 | |
| 100 | 40 | 1 | 1 | 1 | 0.96 | 0.09 | |
| 160 | 20 | 0.98 | 0.95 | 0.94 | 0.88 | 0.04 | |
| 160 | 30 | 0.99 | 0.98 | 0.97 | 0.91 | 0.05 | |
| 160 | 40 | 1 | 0.99 | 0.98 | 0.93 | 0.05 | |
| 2 g q24 h | 40 | 20 | 1 | 1 | 1 | 0.98 | 0.38 |
| 40 | 30 | 1 | 1 | 1 | 0.99 | 0.46 | |
| 40 | 40 | 1 | 1 | 1 | 0.99 | 0.50 | |
| 100 | 20 | 1 | 0.99 | 0.99 | 0.96 | 0.16 | |
| 100 | 30 | 1 | 1 | 1 | 0.97 | 0.21 | |
| 100 | 40 | 1 | 1 | 1 | 0.98 | 0.28 | |
| 160 | 20 | 0.99 | 0.98 | 0.97 | 0.92 | 0.08 | |
| 160 | 30 | 1 | 0.99 | 0.99 | 0.95 | 0.10 | |
| 160 | 40 | 1 | 1 | 1 | 0.96 | 0.13 | |
| 1 g q12h | 40 | 20 | 1 | 1 | 1 | 0.99 | 0.54 |
| 40 | 30 | 1 | 1 | 1 | 0.99 | 0.55 | |
| 40 | 40 | 1 | 1 | 1 | 1 | 0.52 | |
| 100 | 20 | 1 | 1 | 1 | 0.99 | 0.34 | |
| 100 | 30 | 1 | 1 | 1 | 0.99 | 0.38 | |
| 100 | 40 | 1 | 1 | 1 | 0.99 | 0.38 | |
| 160 | 20 | 1 | 1 | 1 | 0.97 | 0.18 | |
| 160 | 30 | 1 | 1 | 1 | 0.98 | 0.23 | |
| 160 | 40 | 1 | 1 | 1 | 0.98 | 0.26 | |
| 2 g q12h | 40 | 20 | 1 | 1 | 1 | 1 | 0.79 |
| 40 | 30 | 1 | 1 | 1 | 1 | 0.82 | |
| 40 | 40 | 1 | 1 | 1 | 1 | 0.84 | |
| 100 | 20 | 1 | 1 | 1 | 0.99 | 0.64 | |
| 100 | 30 | 1 | 1 | 1 | 1 | 0.70 | |
| 100 | 40 | 1 | 1 | 1 | 1 | 0.74 | |
| 160 | 20 | 1 | 1 | 1 | 0.99 | 0.44 | |
| 160 | 30 | 1 | 1 | 1 | 0.99 | 0.51 | |
| 160 | 40 | 1 | 1 | 1 | 1 | 0.57 | |
| 1 g q8h | 40 | 20 | 1 | 1 | 1 | 1 | 0.70 |
| 40 | 30 | 1 | 1 | 1 | 1 | 0.71 | |
| 40 | 40 | 1 | 1 | 1 | 1 | 0.68 | |
| 100 | 20 | 1 | 1 | 1 | 0.99 | 0.55 | |
| 100 | 30 | 1 | 1 | 1 | 1 | 0.56 | |
| 100 | 40 | 1 | 1 | 1 | 1 | 0.54 | |
| 160 | 20 | 1 | 1 | 1 | 0.99 | 0.39 | |
| 160 | 30 | 1 | 1 | 1 | 0.99 | 0.42 | |
| 160 | 40 | 1 | 1 | 1 | 1 | 0.43 | |
| 2 g q8h | 40 | 20 | 1 | 1 | 1 | 1 | 0.87 |
| 40 | 30 | 1 | 1 | 1 | 1 | 0.89 | |
| 40 | 40 | 1 | 1 | 1 | 1 | 0.90 | |
| 100 | 20 | 1 | 1 | 1 | 1 | 0.80 | |
| 100 | 30 | 1 | 1 | 1 | 1 | 0.83 | |
| 100 | 40 | 1 | 1 | 1 | 1 | 0.85 | |
| 160 | 20 | 1 | 1 | 1 | 1 | 0.72 | |
| 160 | 30 | 1 | 1 | 1 | 1 | 0.77 | |
| 160 | 40 | 1 | 1 | 1 | 1 | 0.80 | |
| 1-g LD + 2-g CI | 40 | 20 | 1 | 1 | 1 | 1 | 0.97 |
| 40 | 30 | 1 | 1 | 1 | 1 | 0.98 | |
| 40 | 40 | 1 | 1 | 1 | 1 | 0.97 | |
| 100 | 20 | 1 | 1 | 1 | 1 | 0.92 | |
| 100 | 30 | 1 | 1 | 1 | 1 | 0.92 | |
| 100 | 40 | 1 | 1 | 1 | 1 | 0.91 | |
| 160 | 20 | 1 | 1 | 1 | 1 | 0.87 | |
| 160 | 30 | 1 | 1 | 1 | 1 | 0.87 | |
| 160 | 40 | 1 | 1 | 1 | 1 | 0.87 | |
| 1-g LD + 4-g CI | 40 | 20 | 1 | 1 | 1 | 1 | 1 |
| 40 | 30 | 1 | 1 | 1 | 1 | 1 | |
| 40 | 40 | 1 | 1 | 1 | 1 | 1 | |
| 100 | 20 | 1 | 1 | 1 | 1 | 0.99 | |
| 100 | 30 | 1 | 1 | 1 | 1 | 0.99 | |
| 100 | 40 | 1 | 1 | 1 | 1 | 0.98 | |
| 160 | 20 | 1 | 1 | 1 | 1 | 0.98 | |
| 160 | 30 | 1 | 1 | 1 | 1 | 0.98 | |
| 160 | 40 | 1 | 1 | 1 | 1 | 0.98 | |
a
LD, loading dose; CI, continuous infusion; CLCR, creatinine clearance; q8, q12, and q24h, administered every 8, 12, and 24 h, respectively.